Jupiter Wellness, Inc. - JUPW STOCK NEWS

Jupiter Wellness (NASDAQ:JUPW) has completed patient recruitment for its clinical trial of JW-200, targeting actinic keratosis (AK), a pre-cancerous skin condition. The trial enrolled approximately 100 patients and aims to report results by Q1 2022. JW-200 is a topical treatment combining cannabidiol and aspartame, designed to clear AK lesions effectively. With an expected market value of $14.55 billion by 2027, successful results could position Jupiter to launch an over-the-counter product, potentially impacting the growing skin cancer treatment market.

Jupiter Wellness (Nasdaq:JUPW) announced that Shannon Soqui, Executive Chairman of its merger partner Next Frontier Pharmaceuticals, was featured on Benzinga's program discussing their merger. The merger has received approval from both companies' boards and is awaiting shareholder and regulatory approval. Soqui highlighted key assets, including the FDA-approved drug SYNDROS and a deep clinical pipeline with potential treatments for Alzheimer's and cancer. The merger aims to position Jupiter for accelerated growth in cannabinoid therapeutics.

Jupiter Wellness (NASDAQ:JUPW) has announced an interview featuring CEO Brian John discussing the merger with Next Frontier Pharmaceuticals. The interview emphasizes Jupiter's potential to hold one of only four FDA-approved cannabis drugs globally post-merger. Shareholder approval is pending, and a proxy statement will be filed soon. The merger is expected to significantly enhance Jupiter's growth and cannabinoid leadership, aligning it with others in the market with large capitalizations.

Jupiter Wellness (NASDAQ:JUPW) announces that its merger partner, Next Frontier Pharmaceuticals, is pursuing FDA fast-track approval for an oral dronabinol solution targeting Alzheimer's Disease Agitation (Agit-AD). Following a successful pre-IND FDA meeting, the company plans to initiate Phase II clinical trials in 2H 2022. With over four million seniors affected by Agit-AD and no FDA-approved treatments available, the drug aims to address a significant unmet medical need. The Phase II trial will involve 160 patients and utilize the Cohen-Mansfield Agitation Inventory as its primary endpoint.

Jupiter Wellness has announced a $5.0 million share buyback program, set to expire on June 30, 2022. This initiative, representing approximately 30% of the company's outstanding shares, aims to acquire around 7 million shares based on current market prices. The program reflects management's confidence in the company's future growth and the planned acquisition of Next Frontier Pharmaceuticals. Funds for the buyback have already been deposited with Oppenheimer & Co Inc., showcasing a strategic use of capital.

Jupiter Wellness (NASDAQ:JUPW) plans to dividend its subsidiary SRM Entertainment to stockholders, with each shareholder receiving one share for every four shares owned. This move coincides with its merger with Next Frontier Pharmaceuticals. The subsidiary aims to raise up to $10 million and list on Nasdaq. The transaction, pending regulatory and shareholder approval, is anticipated to finalize in the next four months. This restructuring is intended to enhance shareholder value and allow Jupiter Wellness to focus on its cannabinoid drug development.

Next Frontier Pharmaceuticals' subsidiary Benuvia has partnered with Global Wellness Strategies and Shanti Therapeutics to enter the psychedelic drug development market. Benuvia, based in Texas, has a facility permitted by the U.S. DEA and registered with the FDA, specializing in synthetic cannabinoids and psychedelic APIs. The agreement focuses on MDMA, with Benuvia providing life cycle management services, toxicology, and clinical trial assistance. This move is expected to enhance the company’s position in the mental health treatment sector.

Jupiter Wellness announced a definitive agreement to acquire Next Frontier Pharmaceuticals, aiming to position itself as a leader in the cannabinoid pharmaceutical market. The acquisition includes one of only four FDA-approved cannabinoid drugs, SYNDROS, and expands Jupiter's clinical pipeline with nine new drug indications. The company operates a fully licensed, 83,000 sq. ft. manufacturing facility and holds numerous patents, enhancing its competitive edge. The management team has substantial pharmaceutical experience, and the transaction is expected to drive revenue and long-term value for stockholders.

Jupiter Wellness (NASDAQ:JUPW) has announced a definitive agreement to acquire Next Frontier Pharmaceuticals through a merger. Next Frontier is the owner of SYNDROS®, an FDA-approved cannabinoid treatment for chemotherapy-induced nausea and vomiting and anorexia in AIDS patients. The acquisition will provide Jupiter Wellness with enhanced drug development capabilities and a significant manufacturing facility in Texas. The deal, unanimously approved by both companies' boards, is expected to close in Q1 2022, focusing on expanding product development in cannabinoids and psychedelics.